Literature DB >> 11752087

A comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods.

M Rusckowski1, T Qu, S Gupta, A Ley, D J Hnatowich.   

Abstract

UNLABELLED: Although a number of different strategies for labeling peptides with (99m)Tc have been developed, only a few studies have compared the in vivo properties of (99m)Tc when attached to different chelators. Furthermore, these comparisons are usually in mice, whereas results obtained in nonhuman primates may be expected to be more relevant to the clinical situation.
METHODS: We evaluated the influence of 4 common chelators on the biodistribution in monkeys of (99m)Tc-labeled HNE-2, a 6.7-kDa peptide being investigated as an inflammation/infection imaging agent. The peptide was conjugated with the N-hydroxysuccinimide ester of mercaptoacetyltriglycine (MAG3), mercaptoacetyltriserine (MAS3), hydrazinonicotinamide (HYNIC), and the cyclic anhydride of diethylenetriaminepentaacetic acid (DTPA). After radiolabeling, each peptide was administered intravenously to rhesus monkeys with a Staphylococcus aureus-induced focal inflammation/infection.
RESULTS: Quantification of radioactivity accumulation by regions of interest over 3 h after administration in monkeys showed important differences among labeling methods: For example, at 3 h, kidney accumulation varied in percentage injected dose per organ (%ID per organ) from 31 %ID per organ (HYNIC) to 18 %ID per organ (MAG3), whereas liver varied from 7.8 %ID per organ (MAG3) to 2.8 %ID per organ (MAS3). Radioactivity accumulation in the lesion was independent of labeling method. These organ accumulations were compared with that obtained earlier in mice by sacrifice and dissection also at 3 h and at the same administered dosage. In the rodent, kidney levels varied from 45 %ID per organ (HYNIC) to 12 %ID per organ (MAS3) and liver levels varied from 6.5 %ID per organ (DTPA) to 2.0 %ID per organ (MAS3).
CONCLUSION: In agreement with previous work from this laboratory and elsewhere, the method of radiolabeling had an important effect on the biodistribution of (99m)Tc. Furthermore, although biodistribution results in mice should be used with caution to predict biodistributions in primates, in major organs, these results in mice and monkeys were similar.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11752087

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

Authors:  Sangeeta Ray Banerjee; Mrudula Pullambhatla; Catherine A Foss; Alexander Falk; Youngjoo Byun; Sridhar Nimmagadda; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2013-07-22       Impact factor: 7.446

2.  Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.

Authors:  Shuping Dou; Yuzhen Wang; Bruce Barton; Ling Chen; Mary Rusckowski; Leonard D Shultz; Dale L Greiner; Guozheng Liu
Journal:  Nucl Med Biol       Date:  2013-10-09       Impact factor: 2.408

3.  (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Authors:  Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-22       Impact factor: 9.236

4.  Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha.

Authors:  Preeti Misra; Djamel Lebeche; Hung Ly; Martina Schwarzkopf; George Diaz; Roger J Hajjar; Alison D Schecter; John V Frangioni
Journal:  J Nucl Med       Date:  2008-05-15       Impact factor: 10.057

5.  99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.

Authors:  Torun Engfeldt; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsen; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-13       Impact factor: 9.236

6.  Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy.

Authors:  Preeti Misra; Valerie Humblet; Nadine Pannier; Wolfgang Maison; John V Frangioni
Journal:  J Nucl Med       Date:  2007-07-13       Impact factor: 10.057

7.  Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3.

Authors:  Anzhelika Vorobyeva; Alexey Schulga; Elena Konovalova; Rezan Güler; John Löfblom; Mattias Sandström; Javad Garousi; Vladimir Chernov; Olga Bragina; Anna Orlova; Vladimir Tolmachev; Sergey M Deyev
Journal:  Sci Rep       Date:  2019-06-28       Impact factor: 4.379

8.  Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.

Authors:  Maryam Oroujeni; Ken G Andersson; Xenia Steinhardt; Mohamed Altai; Anna Orlova; Bogdan Mitran; Anzhelika Vorobyeva; Javad Garousi; Vladimir Tolmachev; John Löfblom
Journal:  Amino Acids       Date:  2018-05-04       Impact factor: 3.520

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.